KNOWLEDGE BANK

Interviews

Interpharm Consultancy

Founder
Interpharm Consultancy has been providing advice about the UK generic market and consultancy services to generic manufacturers and distributors

Articles

Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery

The traditional pharmaceutical approach of designing a diseasesymptomspecific drug has historically proven effective However this methodology often falls short due to the complex and often multifactorial etiology of diseases

Research Insights

Prediction of Clinical Trial Enrollment Rates

Clinical trials represent a critical milestone of translational and clinical sciences However poor recruitment to clinical trials has been a long standing problem affecting institutions all over the world One way to reduce the cost incurred by insufficient enrollment is to minimize initiating trials that are most likely to fall short of their enrollment goal

Case Studies

Effects Of Low-dose Ibuprofen Supplementation And Resistance Training On Bone And Muscle In Postmenopausal Women: A Randomized & Controlled Trial

Abstract Purpose To compare the effects of nine months of exercise training and ibuprofen supplementation given immediately after exercise sessions on bone and muscle in postmenopausal women Methods In a doubleblin

Techno Trends

Indiana University Unveils Ground Breaking New Gene Therapy for Duchenne Muscular Systrophy

Indiana University has introduced a groundbreaking gene therapy technique that restores the fulllength dystrophin protein potentially leading to new treatments for Duchenne muscular dystrophy

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Chemistry & AI

Ashok Kumar

Dr. Ashok Kumar FRSC, President of the Centre for Research & Development at Ipca, earned his PhD from CDRI with Dr. Nityanand and post-doctoral experience from Sussex University with Nobel Laureate Prof. Cornforth. His interests include Chemical, Biotechnological & NDDR research and also integrating spirituality, philosophy, and common sense in his professional and personal life.

2

The Therapeutics Landscape of Miniproteins

Victor H Bustos

Victor H. Bustos, Ph.D., is the Vice President of Preclinical R&D at Ordaos Bio. A specialist in protein engineering with a doctorate in Biomedicine, he leads the design of AI-generated mini-proteins. Previously, he spent 17 years at Rockefeller University focusing on complex cellular mechanisms and therapeutic target validation.

Alena Romanova

Alena Romanova is a Scientist I at Ordaos Bio, where she develops experimental workflows for protein characterisation and biologics discovery, including the application of cell-free protein expression and biochemical assays.

3

The Regulatory Landscape for Nutraceuticals

Suresh Garg

Suresh Garg is the CMD and Founder of Zeon Life Sciences. He has over 30 years of extensive experience in the fields of nutrition, dairy products, healthcare, and nutraceuticals. Under his leadership, Zeon has become a pioneer in contract manufacturing for nutraceuticals and herbal goods. Owing to his passion and ability to thrive in a variety of sociocultural environments, Zeon has entered international markets.

 

4

Precision medicine for Alzheimer’s Disease

Dr. Parmi Tripathi

Dr Parmi is a scientific researcher and an expert medical writer with Ph.D specialising in neurosciences. With an extensive pharmaceutical and healthcare industry experience, she excels at driving innovation. Focused at patient’s centricity, she has played key role in developing innovative medicines that makes meaningful impact on patient’s lives. Dr Parmi has made significant contribution at establishing a patented mouth-dissolving strip (MDS) manufacturing facility. With proven expertise in novel product development, her strong emphasis on quality manufacturing has led to structuring of quality documentation practices for this novel & patented MDS technology aligned with regulatory standards.

Dr Parmi has made significant contributions in field of neuroscience research with multiple acclaimed publications. A distinguished medical writer, she serves as editorial board member and peer reviewer in prestigious journals and continuous to make an impact in her field. Author at reputed public health platform, she writes to promote health awareness. Recognised for her exceptional contributions, she is a multiple-time government R&D grant recipient, particularly in neurodegenerative disorder studies.

5

Changing Paradigms in Use of AI in Chemical Sciences

Prashant S. Kharkar

Prashant S. Kharkar, a well-respected Drug Discovery Researcher with rich industrial experience, received his B. Pharm. degree in 1998. He obtained his PG and Ph.D. (Tech.) degrees Institute of Chemical Technology (ICT), Mumbai, India. Dr. Kharkar completed his postdoctoral research (2006–2009) on neurodegenerative diseases and disorders.

Akash S. Sirsat

Akash Sirsat is pursuing M.Tech in Pharmaceutical Chemistry and Technology at the Institute of Chemical Technology (ICT), Mumbai. He completed his Bachelor of Pharmacy from Sinhgad Institute’s SKNCOP, Pune. His research interests include pharmaceutical chemistry, process development, and applications of AI/ML in pharmaceutical synthesis. He has qualified GPAT, GATE, NIPER, and GAT-B.

press releasesRead more...

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...

Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus

Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited a global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines today announced the submissi...

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Inc a global commercialstage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases today announced the commercial launch of IMCIVREE setmelanotide in Japan to treat patients living with acquired hypothalamic obesity HO...

Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Scinai Immunotherapeutics Ltd a biopharmaceutical company operating a growing contract development and manufacturing organization CDMO alongside an immunologyfocused therapeutic development platform today announced that its wholly owned subsidiary Scinai Biopharma Services Ltd has entered into a def...

EventsRead more...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

PM& AC 2026

Novotel Hyderabad Convention C...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWSRead more...

Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ

Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals

Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours

Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...

Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases

Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...

Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors

Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...

Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada

Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation